3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Purity >99.0% Lenalidomide Intermediate Factory
Ko Ruifu Chemical te kaihanga matua o 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) me te kounga teitei, te takawaenga o Pomalidomide (CAS: 19171-19-8).Ka taea e Ruifu Chemical te tuku i te ao, te utu whakataetae, te ratonga pai, te iti me te rahinga e waatea ana.Hokona 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
Ingoa matū | 3-Aminopiperidine-2,6-Dione Hydrochloride |
Nga kupu taurite | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
Tau CAS | 24666-56-6 |
CAS e pa ana | 2686-86-4;25181-50-4 |
Tūnga Taonga | I roto i te Stock, Production Tauine Up ki Taranata |
Tātai rāpoi | C5H9ClN2O2 |
Taumaha rāpoi | 164.59 |
Te Whakarewa | 120 ℃ |
COA & MSDS | Kei te waatea |
Taketake | Shanghai, Haina |
Waitohu | Ruifu Chemical |
Tūemi | Whakatakotoranga |
Te ahua | Paura Kiriata-White |
Te Maama / Tikanga Tatauria | >99.0% (HPLC) |
makuku (KF) | <0.50% |
Ngaronga i te whakamaroke | <0.50% |
Te toenga i runga i te mura | <0.20% |
Nga poke katoa | <1.00% |
Spectrum Infrared | He rite ki te Hanganga |
Paerewa Whakamatau | Paerewa hinonga |
Whakamahinga | Takawaenga o Lenalidomide (CAS: 191732-72-6) |
Mōkī: Pounamu, Peeke konumohe konumohe, 25kg / Kaata Drum, kia rite ranei ki te hiahia a te kaihoko
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Tiaki i te marama me te makuku
![1](https://a395.goodao.net/uploads/15.jpg)
![www.ruifuchem.com](https://a395.goodao.net/uploads/Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchemical.com_3.png)
Ko te 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) he takawaenga mo te whakarite Lenalidomide (CAS: 191732-72-6).Ko te Lenalidomide tetahi momo rongoa antitumor i whakawhanakehia e nga kamupene rongoa koiora o Amerika.He maha nga mahi penei i te anti-tumor, te ture aukati me te anti-angiogenesis.Ka taea e ia te aukati i te hunanga o nga cytokines inflammatory, me te whakanui ake i te hunanga o nga cytokines anti-inflammatory mononuclear toto peripheral.Ka taea te aukati i te tipu o nga pūtau myeloma maha me te pūtau MM1S.E rua nga rangahau haumanu e whakahaerehia ana e te placebo-a-waahi-a-whare maha e arotake ana i te haumaru me te hua whakaora o te lenalidomide e whakamahia ana mo te myeloma maha.Ko nga hua rangahau haumanu tata nei e whakaatu ana ko te lenalidomide ehara i te mea he rongoa mo te rongoa MDS me te MM, engari ano hoki mo te rongoa i te myeloma, te kanisia, te mate pukupuku o te tinana o te tinana, te pukupuku totoka, te amyloidosis whanui idiopathic me te mate o te wheua wheua fibrosis mate ki te hinu.I te Hakihea 2005, ka whakaaetia e te US Food and Drug Administration (FDA) te lenalidomide hei whakamahi i te maimoatanga o te mate myelodysplastic (MDS).